CLOPIRAC

Details

Stereochemistry	ACHIRAL
Molecular Formula	C14H14ClNO2
Molecular Weight	263.719
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC1=CC(CC(O)=O)=C(C)N1C2=CC=C(Cl)C=C2

InChI

InChIKey=SJCRQMUYEQHNTC-UHFFFAOYSA-N

InChI=1S/C14H14ClNO2/c1-9-7-11(8-14(17)18)10(2)16(9)13-5-3-12(15)4-6-13/h3-7H,8H2,1-2H3,(H,17,18)

HIDE SMILES / InChI

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12259 | Lombardino, J. G.. (1985) Nonsteroidal antiinflammatory drugs, page 292, retrieved from: https://books.google.ru/books?id=HQxtAAAAMAAJ | https://www.ncbi.nlm.nih.gov/pubmed/1228197 | https://www.ncbi.nlm.nih.gov/pubmed/1228198 | https://www.ncbi.nlm.nih.gov/pubmed/1228200

Clopirac is a non-steroidal anti-inflammatory drug. It is a weak inhibitor of prostaglandin synthetase and has standard anti-inflammatory and analgesic activity. It effectivity inhibits prostaglandin synthesis in vitro. The metabolites of clopirac in humans and monkeys include the glucuronide of clopirac and the pyrrole carboxylic acid. Efficacy of clopirac in rheumatoid arthritis, trauma conditions, osteoarthritis and pain was evaluated in many clinical trials.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Prostaglandin synthetase 1 Target ID: Prostaglandin synthetase Sources: Lombardino, J. G.. (1985) Nonsteroidal antiinflammatory drugs, page 292, retrieved from: https://books.google.ru/books?id=HQxtAAAAMAAJ	Inhibitor 8297		230.0 µM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Rheumatoid arthritis 316 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1228193 https://www.ncbi.nlm.nih.gov/pubmed/1228200 https://www.ncbi.nlm.nih.gov/pubmed/777001 https://www.ncbi.nlm.nih.gov/pubmed/776999 https://www.ncbi.nlm.nih.gov/pubmed/776987 https://www.ncbi.nlm.nih.gov/pubmed/776986 https://www.ncbi.nlm.nih.gov/pubmed/776985	Palliative	Not Provided 504	Unknown Approved Use Unknown
Osteoarthritis 157 Sources: https://www.ncbi.nlm.nih.gov/pubmed/776990 https://www.ncbi.nlm.nih.gov/pubmed/776989	Palliative	Not Provided 504	Unknown Approved Use Unknown
Trauma 1 Sources: https://www.ncbi.nlm.nih.gov/pubmed/776992 https://www.ncbi.nlm.nih.gov/pubmed/776997 https://www.ncbi.nlm.nih.gov/pubmed/776998 https://www.ncbi.nlm.nih.gov/pubmed/776994 https://www.ncbi.nlm.nih.gov/pubmed/776993	Palliative	Not Provided 504	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
[Studies of the therapeutic effectiveness of clopirac in osteoarthritis (author's transl)].	1975	1228195
Double-blind cross-over study of clopirac and naproxen in rheumatoid arthritis.	1975	1228193
[Open study of clopirac in the treatment of non articular rheumatism (author's transl)].	1975	1084347
[Clopirac effectiveness in traumatology and non articular rheumatisms (author's transl)].	1975	1084346

Patents

Sample Use Guides

In Vivo Use Guide

Rat: 150 mg/kg

Route of Administration: Oral

In Vitro Use Guide

The ability of clopirac to inhibit the conversion of [3H]arachidonic acid into PGE, was measured in a microsomal enzyme preparation isolated from bovine seminal vesicles. The defined IC50 value was about 45 uM.

Name

Type

Language

CLOPIRAC

Official Name

English

CP 172 AP

Code

English

CP-172AP

Code

English

CLOPIRAC [USAN]

Common Name

English

CLOPIRAC [MI]

Common Name

English

Clopirac [WHO-DD]

Common Name

English

BRL-13856

Code

English

BRL 13856

Code

English

1H-PYRROLE-3-ACETIC ACID, 1-(4-CHLOROPHENYL)-2,5-DIMETHYL-

Systematic Name

English

1-(P-CHLOROPHENYL)-2,5-DIMETHYLPYRROLE-3-ACETIC ACID

Systematic Name

English

CP-172-AP

Code

English

clopirac [INN]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C257